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Aromatic L-amino acid decarboxylase (AADC) is a relatively non specific enzyme involved in the biosynthesis of several classical neurotransmitters including dopamine and 5-hydroxytryptamine (5HT; serotonin).
1 AADC does not catalyse the rate limiting step in either pathway, but is rate limiting in the synthesis of 2-phenylethylamine (2PE) which is a positive modulator of dopaminergic transmission and a candidate natural psychotogenic compound. 1 We and others have proposed that polymorphism in AADC resulting in altered 2PE activity might contribute to the pathogenesis of psychosis. 1, 2 In order to test this hypothesis, we have used denaturing high performance liquid chromatography (DHPLC) 3 to screen 3943 bases of the AADC gene and its promoter regions for variants that might affect protein structure or expression in 15 unrelated people with schizophrenia, and 15 unrelated people with bipolar disorder. Three polymorphisms were identified by DHPLC: a insertion/deletion polymorphism in the 5Ј UTR of the neuronal specific mRNA (g.-33-30delAGAG, bases 586-589 of GenBank M77828), a TϾA variant in the non-neuronal exon 1 (g.-67TϾA, GenBank M88070), and a GϾA polymorphism within intron 8 (g.IVS8 +75GϾA, GenBank M84598). Case-control analysis did not suggest that genetic polymorphism in the AADC gene is associated with liability for developing schizophrenia or bipolar disorder. Molecular Psychiatry (2000) 5, 327-331.
AADC is involved, but is not rate limiting in, the biosynthesis of several neurotransmitters including dopamine and 5HT. 1 However, it is rate limiting in the synthesis of 2-phenylethylamine (2PE). 1 2PE is released from dopaminergic neurones by concentration-dependent diffusion and acts as a positive modulator of dopaminergic transmission. 1 Based upon physiological, behavioural and structural similarities between amphetamine and 2PE, Sandler and Reynolds (1976) originally advanced the hypothesis that 2PE is an endogenous psychotogen, 4 a hypothesis that has subsequently been supported by several lines of circumstantial evidence. First, elevated levels of 2-PE have been found in the serum of schizophrenics. 5, 6 Second, increased activity of AADC (a critical determinant of the concentration of 2PE) has been observed in the brains of living schizophrenics. 7 Third, we and others have shown that several psychotogenic drugs (including lysergic acid diethylamide (LSD), phencyclidine (PCP) and vigabatrin) as well as antipsychotic drugs (eg loxapine and halperidol) regulate AADC mRNA in a manner consistent with the hypothesis that 2PE can act as a natural psychotogen. 1, 2, 8, 9 For these reasons, we and others have proposed that genetic polymorphism resulting in altered AADC function might contribute to the pathogenesis of psychosis. 1, 2 In order to test this hypothesis, we have used denaturing high performance liquid chromatography (DHPLC) 3 to screen the AADC gene in patients with schizophrenia or bipolar disorder for variants that might affect protein structure or expression (VAPSEs). 10 The AADC gene maps to chromosome 7p11 (Genome Database Accession Number GDB: 1036717). It has 15 exons (size range 20-400 bases) and spans a genomic distance of greater than 85 kB. 11 There are two alternative first untranslated exons, one of which is utilised in mRNA in neuronal tissue and one which is utilised in non-neuronal tissue. 12 We screened 3943 bases of genomic sequence of AADC. This includes 637 bases of the neuronal 5Ј flanking/promoter sequence and 491 bases of the nonneuronal 5Ј flanking/promoter sequence as well as all 15 exons with the exception of exon 11 which is only 20 bases long and for which there is inadequate flanking sequence available. 11, 12 Also, because of limited intronic sequence, our primers include the 3Ј terminal seven bases of exon 5, the first eight bases of exon 7, the first seven bases of exon 10, the 3Ј terminal six bases of exon 12, and the first eight bases of exon 14. Thus, we have been unable to scan 56/2172 (2.5%) of the bases corresponding to mRNA.
Heteroduplexes were found in three PCR fragments. Sequencing identified these as a 4-bp insertion/ deletion (AGAG) polymorphism in the 5Ј UTR of the neuronal-specific mRNA (g.-33-30delAGAG, bases 586-589 of GenBank M77828), a TϾA variant in the 5Ј flanking region of non-neuronal exon 1 (g.-67TϾA, GenBank M88070), and a GϾA polymorphism at the 75th base of intron 8 (g.IVS8+75GϾA, GenBank M84598).
Of the three variants detected, we have performed a case control association study on only one. This choice was based upon the premise that case control studies are most likely to be successful using polymorphisms that have functional consequences. 10 While we have no information on the functional consequences (if any) of the variants we detected, we chose to study the insertion/deletion polymorphism in the neuronal-specific 5Ј UTR because even though it is non-coding, it was the only common polymorphism we detected within cDNA sequence. We considered it possible that the g.-67TϾA variant in the non-neuronal 5Ј flanking/promoter region might alter gene expression. However, we did not perform a full case control association study using this variant as no further examples of it were found in a total of 236 chromosomes (104 from schizophrenics, 78 from bipolar probands and 54 from control subjects) that we screened. This is therefore is too uncommon to account for even a modest amount of the variance in susceptibility to psychosis, and our samples would not provide much power to detect a putative effect caused by such a rare variant anyway. Finally, we chose not to study the base substitution 75 bases from exon 8 because it did not create or destroy conserved splice sequences and therefore we thought it unlikely (though not impossible) that this variant would alter gene expression or function.
Allele frequencies of the 4-bp deletion in patients and controls are described in Table 1 and the distribution of genotypes given in Table 2 . None of the samples showed a significant departure from HardyWeinberg equilibrium. Note that because of repeated PCR failure, the numbers of samples successfully genotyped is less than the number we attempted to genotype.
For schizophrenia, neither allele frequencies (patients n = 350, controls n = 358, 2 = 0.37, 1 df, OR The results above therefore do not suggest that AADC polymorphism contributes susceptibility to either schizophrenia or bipolar disorder, but there are several important considerations in assessing the significance of these results. First, we have shown in previous blind study designs that DHPLC is a highly efficient method for mutation detection using the methodology applied in this study. 13, 14 We are therefore confident (Ͼ95%) that if subjects in the screening sample carried a sequence variant, we would have detected it, with the caveat that because of sequence limitations, we were unable to screen 2.5% of the mRNA sequence. The second concerns the power of our screening sample. Under the null hypothesis that there are no polymorphisms in this candidate gene associated with either schizophrenia or bipolar disorder, a screening panel consisting of 15 unrelated schizophrenics and 15 unrelated bipolar disorder probands has 95% power to detect polymorphisms with a frequency of 5% in the general population. It is therefore unlikely that we have missed polymorphisms with an allele frequency greater than this in the UK Caucasian population that confer susceptibility to either disorder. Obviously we do not exclude the possibility that there are other common polymorphisms (associated with either disorder or not) in populations with a different genetic background.
The third main consideration concerns the degree of confidence with which we can exclude the hypothesis that the insertion/deletion polymorphism contributes to susceptibility to schizophrenia or bipolar disorder. The upper limit of the 95% CI for the OR by allele is 1.59 in the case of schizophrenia and 1.36 for bipolar disorder. Therefore, we can exclude the possibility (with 95% confidence) that the deletion polymorphism confers even rather modest increases in susceptibility to either disorder, although in common with all similar studies, we cannot exclude very small effects.
We conclude then that it is unlikely that abnormal AADC function makes a primary contribution to liability for developing schizophrenia or bipolar disorder. However, the variants in AADC we report here are candidate polymorphisms for other disorders in which altered dopaminergic transmission has been proposed including ADHD, Parkinson's disease, Alzheimer's disease, Huntington's disease, and substance abuse.
Methods

Comparative sequencing
The AADC gene and its 5Ј flanking region were amplified in 18 fragments of size ranging between 120 and 521 bases (Table 3) . Primers were designed from genomic sequence generously provided by Professor T Nagatsu and Dr H Ichinose, Fujita Health University, Japan.
The sample for comparative sequencing consisted of 15 subjects meeting DSM-IV 15 criteria for schizophrenia and 15 subjects meeting DSM-IV 15 criteria for bipolar disorder. PCR amplification took place using a Hybaid Express Thermocycler (Hybaid, Middx, UK) in a volume of 25 l containing 40 ng of genomic DNA, 25 pmol of each primer, 100 M dNTPs, and 1 unit of Taq DNA Polymerase (Qiagen, Crawley, UK) in the buffer supplied by the manufacturer. The primers, fragment sizes, and PCR conditions are detailed in Tables 3 Molecular Psychiatry and 4. Before DHPLC analysis, PCR products were denatured by heating to 94°C for 1 min, and were then allowed to re-anneal by cooling to 70°C over 25 min. DHPLC was performed using a WAVE DNA fragment analyser (Transgenomic, Santa Clara, CA, USA) as described in detail elsewhere. 13, 14 To allow exhaustive comparative sequencing, the column temperature for DHPLC analysis was determined using two methods for each fragment. The first is an empirical determination of the temperature that results in elution approximately one minute earlier in the gradient compared with non denaturing conditions. 13 The second method uses software to predict optimal temperatures that is freely available on the Internet (http:// insertion.standford.edu/melt.html).
14 Both methods have greater than 95% sensitivity in blind analyses of more than 150 different sequence variants. 13, 14 Where the different methods suggested different optimal column temperatures, both sets of conditions were used. Note that because some fragments have multiple melting domains, they were run at multiple column temperatures.
Where DHPLC analysis suggested that a subject was heterozygous, the PCR products from that individual were sequenced to determine the nature of the polymorphism using either the Thermo Sequenase Cycle Sequencing kit or the Sequenase Version 2.0 T7 DNA Polymerase Sequencing kit as described by the manufacturer (Amersham, Bucks, UK).
Genotyping
Exon 1A primers were used for genotyping the 4-bp insertion/deletion polymorphism. The forward primer was labelled with ␥ 33 P dATP using standard procedures. Genomic DNA was amplified using the conditions described in Tables 3 and 4 . PCR products were separated by electrophoresis on a 6% denaturing polyacrylamide gel and subjected to autoradiography overnight. All autoradiographs were scored independently by two raters.
Exon 1E primers were used for genotyping the g.-67TϾA variant. After amplification from genomic DNA, 8.9 l of PCR product was digested overnight at 37°C in a total volume of 10 l containing 1 unit of Sapl restriction endonuclease (New England Biolabs, Herts, UK). The digestion products were either 445 bp, corresponding to g.-67A, or 347 bp and 98 bp corresponding to g.-67T. The digestion products were separated on a 1% agarose gel.
Case control studies
The schizophrenia case control study was undertaken using 203 unrelated Caucasians born in the UK or Ireland meeting DSM-IV 15 criteria for schizophrenia. These comprised a single member of 138 affected sibpairs ascertained through mental health services and relatives support groups in England and Wales, and 65 unrelated individuals recruited from inpatient and day patient facilities in South Wales. There were 144 males and 59 females. Diagnoses were made using OPCRIT version 3.31, 16 and were based on all available clinical information, including a semi-structured research interview (SCAN 17 or PSE-9 18 ), review of case records and information from relatives and mental health professionals. Local Research Ethics Committee approval was obtained, and subjects gave written informed consent to participate. Two hundred and three control individuals were individually matched to probands for age, sex, and ethnicity from more than 700 blood donors recruited from the local branch of the National Blood Transfusion Service (Wales). Controls were not specifically screened for the absence of psychiatric illness, 19 although the policy of the National Blood Transfusion Service is not to receive donations from individuals who are on medication.
All bipolar subjects were Caucasians born in the UK or Ireland. Probands (n = 219) were recruited from psychiatric outpatient clinics in England and Wales and met DSM-IV 15 criteria for Bipolar I disorder. Diagnoses were determined following a semi-structured interview and examination of case notes as described. 20 Fiftyeight subjects had a definite family history of affective disorder in a first degree relative. Controls (n = 219) were group matched for age, sex and ethnicity from the panel of blood donors described above. Association between affected status and candidate polymorphisms was tested by 2 .
